Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus temozolomide versus temozolomide alone in elderly patients with newly diagnosed glioblastoma
ACTRN12617000267358Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of nivolumab and temozolomide in glioblastoma (GBM) and Gliosarcoma (GS) (2 arms), sponsored by The University of Sydney. Primary endpoint: Overall survival. Started Mar 2018; status: completed.
02
Drugs
nivolumabtemozolomide
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on ACTRN12617000267358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000267358.